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1. Introduction 
The demonstration of strong neuroexcitatory activ- 
ity produced by extracellular application of L-glutamic 
and L-aspartic acid [l-4] has led to biochemical 
studies aimed at defining the membrane sites with 
which these putative neurotransmitters interact 
[S-lo]. The pursuit of the biochemical characteriza- 
tion of the excitatory amino acid receptor sites has 
been conducted along two lines: 
(1) Determination of membrane binding activity 
through the use of radioactively labeled glutamate 
or aspartate [5-81; or 
(2) Measurement of the receptor recognition func- 
tion through the use of radioactively labeled 
kainic acid (2-carboxy-4-isopropenyl-3-pyr- 
rolidine acetic acid) [9,10], a potent neuroexci- 
tatory agent which is presumed to act on the 
excitatory amino acid receptors [ 11,121. 
We have shown that brain synaptic membranes are 
enriched in high affinity L-[3H]glutamic acid binding 
sites which have a number of the pharmacologic char- 
acteristics of the receptor for this excitatory amino 
acid [5,13,14]. It was also shown that this high affm- 
ity glutamate binding activity of synaptic membranes 
is associated with a small molecular weight glycopro- 
tein [ 151. Glutamate binding to this protein exhibits 
a similar pattern of sensitivity to various glutamate 
analogs as does the binding of L-glutamate to the 
synaptic membranes [5,14,15]. However, the binding 
of L-[3H]glutamic acid either to the synaptic mem- 
branes [6,14] or to the purified binding protein [14] 
is not affected by the presence of a 103-fold greater 
concentration of kainic acid. Evidence is provided here 
which is strongly suggestive of the distinct nature of 
the membrane macromolecules which function as the 
binding sites for L-glutamic acid and those for kainic 
acid. 
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2. Materials and methods 
2.1. Membrane preparation and cholate extraction of 
membranes 
Synaptic plasma membranes were obtained after 
osmotic rupturing of the isolated rat brain synapto- 
somes in a hypotonic buffer medium as in [ 161. These 
membranes were suspended in 0.32 M sucrose-5 mM 
Tris-S04--1 mM MgS04--0.5 mM EDTA (PH 7.4) at 
final protein cont. 6-12 mg/ml. The membrane sus- 
pension was divided into small aliquots, quickly frozen 
in liquid nitrogen, ans stored at -80°C. Each mem- 
brane suspension was used within 2-3 weeks of its 
preparation. NaCholate extraction of the synaptic 
membranes was accomplished by rapidly thawing an 
aliquot of membrane suspension at 37’C in sufficient 
volume of a phosphate buffer medium (135 mM 
K-phosphate-O. 11 M sucrose-l mM MgS04 (pH 7.4)) 
to bring to final protein cont. 2-3 mg/ml. This mix- 
ture was incubated at 37’C for 5 min, allowed to stand 
at room temperature for 10 min, and subsequently 
centrifuged at 39 000 X g for 25 min. The membrane 
pellets were resuspended in either 50 mM Tris-HCl 
(pH 7.4) or in 50 mM Tris-HCl buffer which con- 
tained 0.5% (w/v) of Na-cholate. The volume used for 
this resuspension was equal to that used during the 
thawing steps. Following a 45 min incubation at room 
temperature these suspensions were centrifuged at 
100 000 X g for 60 min (4’C). The final supernatant 
(cholate extract) was dialyzed (Spectrapore mem- 
branes Mr cutoff 6000-8000) against a 200-fold vol. 
50 mM Tris-HCl buffer. The membrane pellets were 
resuspended in 50 mM Tri-HCl at final protein cont. 
l-3 mg/ml. The protein concentration of all samples 
was measured by the Lowry procedure [ 171. 
2.2. Binding assays 
The L-glutamate binding activity of all particulate 
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subcellular f actions was measured by a microfuge 
centrifugation assay as in [ 181. p-Chloromercuri- 
phenyl sulfonate was not routinely included in the 
binding assays. Glutamate binding to the soluble 
extract from synaptic membranes was monitored by a 
Millipore filtration assay employing L-[3H]glutamic 
acid (40-50 Cilmmol, New England Nuclear Corp.) as 
in [14]. The binding of [3H]kainic acid (2.4-2.6 Ci/ 
mmol, AmershamlSearle Corp.) to either the synaptic 
membranes or to the cholate extract was measured by 
a Millipore filtration assay. The binding assay involved 
the incubation of 450 fl membrane suspension or of 
cholate extract in 500 ~1 final vol. medium containing 
50 mM Tris-HCl (pH 7.6) with variable amounts of 
[3H]kainic acid. Non-specific binding was determined 
by measuring [jH] kainic acid binding in the presence 
of lo-’ M non-labeled kainic acid. All samples were 
incubated at room temperature for 25 min, the reac- 
tion was stopped with 0.5 ml cold 50 mM Tris-HCl 
buffer, and the samples were immediately filtered 
through Millipore filters (HAWP, 0.45 pm). The filters 
were washed with 0.5 ml Tris-HCl buffer. Non-spe- 
cific binding of [3H]kainic acid to synaptic mem- 
branes consituted 25-50% of the total binding and 
was subtracted from all samples in the calculations of 
the specific binding. 
3. Results and discussion 
The same membrane preparations used for the 
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Fig.1. [‘H]Kainic acid binding to synaptic membranes. Dis- 
placement of specifically bound [3H]kainic acid (17 nM) by 
non-labeled kainic acid (0) and Lglutamate (0). Each data 
point is the mean of 6-15 determinations. Standard error of 
the mean varied from 4-l 2%. 
study of glutamate binding activity were found to 
possess [3H]kainic acid binding sites which were quite 
sensitive to the presence in the incubation medium of 
either non-labeled kainic acid or of non-labeled 
L-glutamic acid (fig.1). The addition of unlabeled 
kainic acid caused aconcentration-dependent displace- 
ment of [3H]kainic acid from its binding sites with an 
estimated concentration for 50% displacement KY,, = 
1 .l X lo-’ M (fig.1). This value is quite similar to the 
K1 (1.2 X lOa M) for kainic acid inhibition of [3H]- 
kainic acid binding to rat brain cerebellar membranes 
measured by a centrifugation assay [lo]. LGlutamic 
acid displaced [ 3H] kainic acid from the membranes 
with an estimated&, = 7.2 X 10-a M (fig.1). Despite 
the fact that both kainic acid and L-glutamic acid 
were active in displacing bound [jH]kainic acid, the 
displacement produced by non-labeled kainate showed 
no cooperativity (Hill coefficient (r@ 0.89) whereas 
that which was brought about by L-glutamate xhib- 
ited negative cooperativity (nH 0.61). These findings 
are very similar to the demonstration [ 191 that kainic 
acid displacement of [3H]kainic acid which was bound 
to rat cerebellar membranes had nH 0.92 whereas dis- 
placement of [jH] kainic acid by L-glutamic acid 
had nH 0.62. These results are suggestive of two dif- 
ferent but interacting binding sites for glutamate and 
kainic acid. 
The probable non-identity of the glutamate and 
kainic acid binding sites in synaptic membranes was 
further substantiated by treating the synaptic mem- 
branes with 0.5% (w/v) Na-cholate (table 1). Treat- 
ment of these membranes with this concentration of 
Na-cholate did not cause a loss of L-[3H]glutamate 
binding activity, but, on the contrary, it led to a 
moderate increase in glutamate binding. However, 
membranes treated with Na-cholate lost -50% of 
kainic acid binding activity (table 1). The lost bind- 
ing activity was traced to the supernatant obtained 
following the cholate extraction and the 100 000 X g 
centrifugation of the cholateextracted membranes, 
while <l% of the glutamate binding activity was 
recovered in this supernatant fraction (table 1). 
When these results are considered with our findings 
that the purified glutamate binding protein from brain 
synaptic membranes does not have any level of inter- 
action with kainic acid [14], then, they indicate that 
the glutamate binding entity is distinct from the macro- 
molecular species which binds kainic acid in the syn- 
aptic membranes. These observations offer an explana- 
tion at the molecular level for the previously determined 
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Table 1 
Effects of cholate treatment of synaptic membranes on [ ‘Hlkainic acid and 
[ ‘HIglutamate binding 
Preparation Protein 
(mg) 
[ ‘H]Kainic Acida [‘H ]Glutamate 
binding binding 
(pmol/mg-’ protein) 
Control membranes 3.15 0.173 f 0.057 5.26 f 0.90 
(7) (4) 
0.5% NaCholate-treated 2.39 0.084 i: 0.055 17.08 + 2.17 
membranes (8) (4) 
Control membrane 0.98 0 0 
supernatant 
0.5% NaCholate soluble 1.93 0.065 f 0.026 0.10 f 0.02 
supernatant (7) (4) 
-- 
a Binding of [3H]kainic acid (17 nM) to all fractions was measured by the Milli- 
pore filtration assay. [3H]Glutamate (92 nM) binding to membranes was mea- 
sured by the microfuge centrifugation assay. AB values are the mean (2 SE) of 
the no. determinations hown in parentheses 
differences in electrophysiologic actions and in neuro- 
pharmacologic characteristics of L-glutamic acid and 
kainic acid excitation in the central nervous system 
[20-231. The methods described here for the physical 
separation of these two membrane binding sites for 
glutamate and kainic acid open up the possibility for 
further characterization of the kainic acid binding sites 
and for further exploration of the possible endogenous 
molecules which normally interact with these sites. 
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